Mancini, Stefano Poirel, Laurent Tritten, Marie-Lise Lienhard, Reto Bassi, Cécile Nordmann, Patrice 2017 The increasing incidence of carbapenem-resistant Klebsiella pneumoniae is a major challenge to public health. Despite the fact that the prevalence of carbapenemases among carbapenem-resistant K. pneumoniae varies geographically, the incidence of OXA-48-like enzymes has soared in recent years and is particularly high in some European countries, such as Spain and France (74% and 78% among carbapenemase-producing K. pneumoniae, respectively).1 A significant number of OXA-48 variants have been reported in the last decade. This includes OXA-232, a carbapenemase firstly identified in France in 20112 and thereafter found in several countries.3,4 Recently, an MDR K. pneumoniae ST231 co-producing OXA-232, the ESBL CTX-M-15 and the 16S rRNA methyltransferase RmtF conferring broad- spectrum resistance to aminoglycosides has emerged as a successful epidemic... application/pdf https://folia.unifr.ch/global/documents/306216 https://folia.unifr.ch/documents/306216/files/nor_emk.pdf eng info:eu-repo/semantics/altIdentifier/doi/10.1093/jac/dkx428 info:eu-repo/semantics/openAccess License undefined Journal of Antimicrobial Chemotherapy. - 2018, vol. 73, no. 3, p. 821-823 info:eu-repo/classification/udc/57 Emergence of an MDR Klebsiella pneumoniae ST231 producing OXA-232 and RmtF in Switzerland http://purl.org/coar/resource_type/c_6501